Cowen reiterated their buy rating on shares of Amicus Therapeutics (NASDAQ:FOLD) in a report issued on Wednesday morning. They currently have a $22.00 price target on the biopharmaceutical company’s stock.
Other equities research analysts have also recently issued research reports about the company. Leerink Swann reaffirmed a buy rating and set a $20.00 price target (up previously from $17.00) on shares of Amicus Therapeutics in a report on Wednesday, October 4th. Bank of America lifted their price target on Amicus Therapeutics from $15.00 to $20.00 and gave the company a buy rating in a report on Wednesday, October 4th. Chardan Capital reiterated a buy rating and set a $18.50 price objective (up previously from $16.50) on shares of Amicus Therapeutics in a research note on Thursday, October 5th. Zacks Investment Research upgraded shares of Amicus Therapeutics from a hold rating to a buy rating and set a $16.00 price objective on the stock in a research note on Tuesday, October 10th. Finally, BidaskClub upgraded shares of Amicus Therapeutics from a hold rating to a buy rating in a research note on Wednesday, December 27th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of $18.31.
Shares of Amicus Therapeutics (NASDAQ:FOLD) opened at $15.72 on Wednesday. The firm has a market capitalization of $2,638.69, a P/E ratio of -8.59 and a beta of 1.72. The company has a current ratio of 6.32, a quick ratio of 6.22 and a debt-to-equity ratio of 0.39. Amicus Therapeutics has a twelve month low of $5.07 and a twelve month high of $16.60.
Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.10). The business had revenue of $10.90 million for the quarter, compared to the consensus estimate of $9.02 million. Amicus Therapeutics had a negative net margin of 1,092.37% and a negative return on equity of 63.54%. The business’s quarterly revenue was up 419.0% on a year-over-year basis. During the same period last year, the firm posted ($0.33) EPS. sell-side analysts forecast that Amicus Therapeutics will post -1.56 EPS for the current year.
In related news, SVP Daphne Quimi sold 8,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $14.72, for a total transaction of $117,760.00. Following the transaction, the senior vice president now owns 62,676 shares in the company, valued at $922,590.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jay Barth sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $14.71, for a total transaction of $73,550.00. Following the transaction, the insider now owns 69,184 shares in the company, valued at approximately $1,017,696.64. The disclosure for this sale can be found here. Insiders have sold 718,920 shares of company stock worth $10,263,669 in the last quarter. Company insiders own 3.40% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of FOLD. Strs Ohio acquired a new position in Amicus Therapeutics in the third quarter worth approximately $102,000. Birchview Capital LP acquired a new position in Amicus Therapeutics in the third quarter worth approximately $151,000. Sage Capital Advisors llc acquired a new position in Amicus Therapeutics in the third quarter worth approximately $154,000. Engineers Gate Manager LP acquired a new position in Amicus Therapeutics in the third quarter worth approximately $155,000. Finally, Tudor Investment Corp ET AL acquired a new position in Amicus Therapeutics in the second quarter worth approximately $124,000.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.